Informing humanitarians worldwide 24/7 — a service provided by UN OCHA

Nigeria

Yellow Fever Outbreak in Nigeria: NCDC Situation Report #35 (8 - 14 October 2018)

Attachments

HIGHLIGHTS

In this reporting week 8 th October – 14th October, 2018:

o There were 78 suspected cases reported

o Seven presumptive positive cases and two inconclusive cases were reported from two of the diagnostic laboratories as outlined below:

  • The NCDC Central Public Health Laboratory (CPHL) reported two inconclusive cases from [-1 Abia (Umuahia South, LGA), Imo -1 (Ezinihitte LGA)]

  • Kaduna Yusuf Dansoho Memorial Hospital (YDMH) reported seven presumptive positive cases; from [Jigawa -1 Guri LGA, Kebbi -5 (Ngaski LGA -4 and Shanga LGA -1) and Sokoto – 1 Gada LGA)].

o The last Institut Pasteur Dakar (IP Dakar) confirmed case from Nigeria was on 6 th June, 2018 from Rivers State

o A three year (2019-2021) Yellow fever (YF) Preventive Mass Vaccination Campaign (PMVC) proposal plan developed

SUMMARY OF OUTBREAK

  • A yellow fever outbreak is currently active in Nigeria. Confirmed cases have been recorded in eleven States (Kwara, Kogi, Kano, Zamfara, Kebbi, Nasarawa, Niger, Katsina, Edo, Ekiti and Rivers States): in 22 Local Government areas (LGAs) [Table 1]

  • Since the beginning of the outbreak, 155 samples (presumptive positive -133 and inconclusive -22) in 77 LGAs have been sent to IP Dakar for re-confirmation [Figure 1]

  • Since the beginning of the outbreak, all Nigerian states have reported suspected cases in 566 (73.1%) LGAs

  • From the onset of this outbreak in September 12, 2017, a total of 3,240 suspected yellow fever cases have been reported as at week 41 [8 th October – 14th October, 2018 (Table 1)].

  • Of the 3,240 suspected cases, 2,985 (92.1%), had blood samples collected and sent to the Nigerian testing laboratories for confirmation

  • Of the 2,985 samples collected, 133 (4.5%) tested positive for yellow fever (presumptive positive cases) and 22 (0.7%) inconclusive results in six Nigerian laboratories (Table 1)